Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Pharmacology, Toxicology and Pharmaceutical Science
16
4%
Agricultural and Biological Sciences
13
3%
Other
29
7%
Unknown
180
43%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 88. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2025.
All research outputs
#604,344
of 33,953,699 outputs
Outputs from Journal of Clinical Oncology
#1,301
of 31,521 outputs
Outputs of similar age
#9,682
of 359,598 outputs
Outputs of similar age from Journal of Clinical Oncology
#27
of 158 outputs
Altmetric has tracked 33,953,699 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 31,521 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,598 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.
